Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan/FLAG Conditioning in Relapsed/Refractory Acute Leukemia
NCT02784561Phase 4Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2016
- Primary completion
- Jul 2019
- Modality
- Orthosteric Ligands, Cytokines & Interferons, Metabolically Activated Prodrugs
01
Overview
Phase 4, open-label trial of busulfan, fludarabine, cytarabine and granulocyte colony-stimulating factor in acute leukemia, sponsored by Chinese PLA General Hospital. Primary endpoint: Number of participants with relapse at 2 years. Status: unknown.
02
Drugs
busulfanfludarabinecytarabinegranulocyte colony-stimulating factor
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT02784561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784561.